Cosciens Biopharma Inc (CSCI.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Sales | 7,498 | 9,587 | 7,262 | 13,881 | 13,486 |
| Cost of Goods | 4,851 | 4,858 | 4,280 | 5,763 | 5,887 |
| Gross Profit | 2,647 | 4,729 | 2,982 | 8,118 | 7,599 |
| Operating Expenses | 13,012 | 18,752 | 7,698 | 4,066 | 5,542 |
| Operating Income | -10,365 | -14,023 | -4,715 | 4,052 | 2,058 |
| Interest Expense | 168 | 129 | 97 | 96 | 119 |
| Other Income | 185 | -1,073 | 361 | 301 | 116 |
| Pre-tax Income | -10,348 | -15,225 | -4,451 | 4,256 | 2,054 |
| Income Tax | 10 | 84 | -901 | 1,016 | -175 |
| Net Income Continuous | -10,358 | -15,309 | -3,550 | 3,241 | 2,229 |
| Net Income | $-10,358 | $-15,309 | $-3,550 | $3,241 | $2,229 |
| EPS Basic Total Ops | -3.27 | -5.93 | -1.92 | 1.87 | 1.33 |
| EPS Basic Continuous Ops | -3.27 | -5.93 | -1.92 | 1.87 | 1.33 |
| EPS Diluted Total Ops | -3.27 | -5.93 | -1.92 | 1.87 | 1.33 |
| EPS Diluted Continuous Ops | -3.27 | -5.93 | -1.92 | 1.87 | 1.33 |
| EBITDA(a) | $-8,992 | $-13,489 | $-2,887 | $5,761 | $3,648 |